dulaglutide: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
dulaglutide: clinical details
Prescribing considerations
- Confirm type 2 diabetes; dulaglutide is not a substitute for insulin and must not treat diabetic ketoacidosis.
- Use caution with previous pancreatitis and do not restart if pancreatitis is confirmed.
- It is not recommended in severe gastrointestinal disease, including severe gastroparesis.
- Experience in end-stage renal disease is very limited, so the selected product is not recommended in this population.
- Record the product name and batch number for traceability.
- Ensure the anaesthetic team knows about treatment before general anaesthesia or deep sedation because delayed gastric emptying may increase aspiration risk.
Contraindications and cautions
- Hypersensitivity to dulaglutide or any formulation excipient.
Monitoring
- Assess glycaemic response using appropriate diabetes measures.
- Monitor gastrointestinal tolerability, hydration and renal function when vomiting or diarrhoea is significant or persistent.
- Monitor for hypoglycaemia with insulin or a sulfonylurea.
- Investigate persistent severe abdominal pain promptly for pancreatitis; isolated pancreatic-enzyme elevation does not predict pancreatitis.
- Review new severe gastric-emptying symptoms and consider treatment modification or discontinuation.
Clinical pharmacology
Dulaglutide is a recombinant, long-acting GLP-1 receptor agonist resistant to DPP-4 degradation. It increases glucose-dependent insulin secretion, suppresses glucagon, reduces hepatic glucose output and delays gastric emptying. It is degraded through general protein-catabolism pathways rather than conventional hepatic metabolism.
Formulation and product differences
- The selected presentations are clear, colourless solutions in disposable single-use pre-filled pens.
- Multiple pen strengths exist; verify the prescribed presentation before supply or administration.
- Pens must not be reused or mixed with another medicine.
dulaglutide preparations and strengths
Injection
Route: Parenteral
Strengths: 0.75 mg, 1.5 mg, 3 mg, 4.5 mg
dulaglutide interactions
Dulaglutide has few demonstrated clinically important pharmacokinetic interactions, but its glucose-lowering effect and delayed stomach emptying can affect other treatment.
Insulin
The combination increases hypoglycaemia risk. Glucose monitoring and a carefully supervised insulin review may be required, without abrupt insulin withdrawal.
Sulfonylureas
The combination increases hypoglycaemia risk, so treatment may need prescriber review.
Oral medicines requiring rapid or predictable absorption
Delayed stomach emptying may alter absorption, particularly when dulaglutide is first introduced. Review medicines with a narrow therapeutic margin or prolonged-release formulation.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.